MGTX supply chain intelligence for MeiraGTx Holdings plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GOLDMAN-SACHS-CO-LLC | GOLDMAN-SACHS-CO-LLC | 92% | On April 16, 2026, MeiraGTx Holdings plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and Goldman Sachs & Co. LLC (the “Underwriter… |
| PERCEPTIVE-CREDIT-HOLDINGS-III-LP | PERCEPTIVE-CREDIT-HOLDINGS-III-LP | 92% | Perceptive Credit Holdings III, LP, as administrative agent and noteholder under the Notes Purchase Agreement |
| HOLOGEN-LIMITED | HOLOGEN-LIMITED | 90% | On the Initial Closing Date, (B) MeiraGTx Manufacturing Limited, a private company limited by shares incorporated in England ("MeiraGTx Manufacturing"), MeiraGTx Limited, a private company limited by… |
| JANSSEN | JANSSEN | 90% | On April 15, 2026, the Company entered into an agreement to reacquire the RPGR Product from Janssen and terminate the Original Asset Purchase Agreement and the Supply Agreement. |
| UCLB | UCLB | 90% | Under the terms of the Third UCLB License Agreement, we paid an initial upfront payment of £6,994, and issued to UCLB £100,000 of our ordinary shares. |
| JNJ | Johnson & Johnson | 72% | O CONSOLIDATED FINANCIAL STATEMENTS or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of checking and money market accounts held at large international banks… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from JNJ grap… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MGTX graph: acture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a QC hub perfor… |
| LLY | Eli Lilly and Company | 72% | acture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a QC hub performing advanced biochemical quality control testing for MeiraGTx clinical and comme… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: Reciprocal relationship from MGTX graph: acture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a QC hub perfo… |
| VYGR | Voyager Therapeutics, Inc. | 72% | acture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a QC hub performing advanced biochemical quality control testing for MeiraGTx clinical and comme… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PERCEPTIVE-MASTER-FUND | PERCEPTIVE-MASTER-FUND | 92% | MeiraGTx Holdings plc (the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with Perceptive Life Sciences Master Fund, Ltd. (“Perceptive Master Fund”), an affiliate… |
| HOLOGEN | HOLOGEN | 85% | On April 20, 2026 (the "Initial Closing Date"), MeiraGTx Holdings plc (the "Company") and certain of its affiliates completed the initial closing of the strategic collaboration with Hologen Limited, … |
| JOHNSON-JOHNSON-INNOVATIVE-MEDICINE | JOHNSON-JOHNSON-INNOVATIVE-MEDICINE | 85% | MeiraGTx UK II Limited agreed to manufacture and supply the RPGR Product for Johnson & Johnson Innovative Medicine |
| JNJ | Johnson & Johnson | 72% | TX HOLDINGS PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS million non-refundable upfront fee from Johnson & Johnson Innovative Medicine and during the year ended December 31, 2021… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from JNJ grap… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MGTX-DEBT | Debt stack $87.5M | 90% | Market cache reports total debt of $87.5M. |
| MGTX-DEBT-10970 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2018-12-31. |
| MGTX-DEBT-10969 | Warrants outstanding: 2.7 | 90% | xbrl warrant detail from xbrl 2018-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MGTX-OWNER-PERCEPTIVE-ADVISORS-LLC | PERCEPTIVE ADVISORS LLC | 90% | 13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 133 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 |